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TumorDNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their
clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-
selective DNA damage. Various strategies have been developed to circumvent the shortcomings of
platinum-based chemotherapy but the inherent problem remains unsolved. Here we report that plat-
inum pyrithione (PtPT), a chemically well-characterized synthetic complex of platinum, inhibits protea-
some function and thereby exhibits greater and more selective cytotoxicity to multiple cancer cells than
cisplatin, without showing discernible DNA damage both in vitro and in vivo. Moreover, unlike the clas-
sical proteasome inhibitor bortezomib/Velcade which inhibits the proteasome via blocking the peptidase
activity of 20S proteasomes, PtPT primarily deactivates 26S proteasome-associated deubiquitinases
USP14 and UCHL5. Furthermore, PtPT can selectively induce cytotoxicity and proteasome inhibition in
cancer cells from leukemia patients but not peripheral blood mononuclear cells from healthy humans.
In nude mice, PtPT also remarkably inhibited tumor xenograft growth, without showing the adverse
effects that were induced by cisplatin. Hence, we have discovered a new platinum-based anti-tumor
agent PtPT which targets 26S proteasome-associated deubiquitinases rather than DNA in the cell and
thereby exerts safer and more potent anti-tumor effects, identifying a highly translatable new
platinum-based anti-cancer strategy.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chemotherapy using cisplatin, the platinum coordination com-
plex cis-diamminedichloroplatinum (II) (CDDP), is a prevailing
paradigm for the use of metal medicine in cancer treatment [1].
However, severe side effects resulting from the poor specificity of
cisplatin and the acquired or intrinsic resistance to cisplatin signif-
icantly restrict its clinical use and efficacy against various cancers
[2]. Cisplatin interacts with DNA by the N7 site of guanine and ade-nine bases, forming DNA adducts, and thereby interfering with
DNA replication and transcription [3], which constitutes the pri-
mary biochemical mechanism of cisplatin’s powerful anti-tumor
effects but non-discriminatively targeting DNA by cisplatin also
causes severe consequences to normal cells, yielding serious
adverse effects and limiting its use. The limitations of cisplatin
have stimulated intensive search for additional platinum-based
anticancer drugs. For example, carboplatin and oxaliplatin are
two of FDA-approved platinum-based drugs with somewhat
improved therapeutic properties but they all operate via a similar
non-specific mechanism of action; therefore, they retain most of
the undesirable effects of cisplatin [4].
With the growing understanding of the molecular biology of the
ubiquitin–proteasome system (UPS) and the success in clinical use
of proteasome inhibitors (e.g., bortezomib, carfilzomib) to treat
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attractive strategy for cancer therapy [5]. The UPS consists of three
main components including the ubiquitin-conjugating system, the
deubiquitinating enzymes (DUBs), and the proteasome [6,7]. Since
the UPS is the pivot of protein degradation, deubiquitination of
tagged proteins by DUBs is essential for regulating proteasome-
mediated degradation, and has been implicated in the pathogene-
sis of many human diseases, including cancer [8]. Unlike 20S pro-
teasome inhibitor, most of reported DUB inhibitors can specifically
target one or several DUBs by which distinctive proteins are regu-
lated. Interference with the ubiquitin deconjugation may generate
more specific and less toxic anticancer agents.
The human genome encodes 98 putative DUBs [9]. Three of
them, including USP14, UCHL5 and RPN11 are known to associate
with the 26S proteasome (26S). USP14 and UCHL5 are cysteine
proteases, belonging to the ubiquitin-specific protease (USP) and
the ubiquitin C-terminal hydrolase (UCH) families, respectively.
RPN11 or POH1 is a metalloprotease, belonging to the JAMM
domain family of DUBs. These DUBs edit polyubiquitin chains on
proteasome substrates for protein degradation [10,11]. Due to
the great potential for DUBs to become therapeutic targets in can-
cer, several small molecule inhibitors and natural compounds have
been developed. Some of these inhibitors are broad spectrum,
while others are very specific, targeting only a particular DUB. Sev-
eral DUB inhibitors have emerged from preclinical testing [12].
In the present study, we have identified a new platinum-based
anti-tumor agent PtPT which targets 26S proteasome-associated
DUBs rather than DNA in the cell and thereby exerts safer and
potent anti-tumor effects; hence, a highly promising and easily
translatable new platinum-based anti-cancer strategy is experi-
mentally demonstrated.2. Materials and methods
2.1. Cell culture
K562 (chronic myelogenous leukemia), HEK293 (human embry-
onic epithelial cells), U266 (myeloma cells), SMMC-7721 (Human
hepatoma cells), 16HBE (non-transformed bronchial epithelial
cells) and L02 (normal liver cells) were purchased from American
Type Culture Collection (Manassas, VA, USA), A549 and cisplatin-
resistant A549/DDP were a gift of Dr. Z. He (Cancer Hospital and
Cancer Research Institute of Guangzhou Medical University). Most
of cell lines were grown in RPMI 1640 (Gibco-Invitrogen, Carlsbad,
CA, USA) supplemented with 10% FBS, 100 units/ml of penicillin
and 100 g/ml of streptomycin. A549/DDP cells were routinely
maintained in the same medium but in the presence of 1.5 lg/ml
cisplatin, which was removed before experiments were started
by a wash-out period of 2–3 days. HEK293 cultured in DMEMmed-
ium with high glucose supplemented with 10% fetal bovine serum
(HyClone, Logan, UT, USA). GFPu, a green fluorescence protein
(GFP) modified by carboxyl fusion of degron CL1, was previously
proven a specific surrogate substrate for the UPS [13]. HEK-293
cells stably harboring GFPu were created as we previously
described [14].2.2. Blood samples and isolation of peripheral blood monocytes
Peripheral blood samples of normal controls were obtained
from Guangzhou Blood Center and peripheral bone marrow sam-
ples of AML patients were obtained from discarded material uti-
lized for routine laboratory tests at the Department of
Hematology, Guangzhou First Municipal People’s Hospital of
Guangzhou Medical University; the use of these materials is
approved by the Ethics Committee of these two Institutions withthe permission of the patients and volunteers. Totally six patients
with AML and six volunteers were recruited in this preclinical
study. Mononuclear cells were isolated by Ficoll-Paque (Pharmacia,
Uppsala, Sweden) density gradient. Mononuclear cell fraction was
cultured in RPMI 1640 culture medium with 15% FBS.
2.3. Reagents and antibody
PtPT was synthesized in our lab. Other agents are bortezomib
(BD Biosciences, San Jose, CA); NEM, Penicillin, Streptomycin, Cis-
platin (Sigma–Aldrich Inc., St. Louis, MO); b-AP15, Suc-Leu-Leu-V
al-Tyr-aminomethylcoumarin (Suc-LLVY-AMC), Z-Leu-Leu-Glu-
AMC (Z-LLE-AMC), Boc-Leu-Arg-Arg-AMC (Boc-LRR-AMC), 19S,
20S and 26S human proteasomes, HA-Ubiquitin-Vinyl Sulfone
(HA-Ub-VS), K48-linked tetra-ubiquitin, ubiquitin-AMC (U550)
(BostonBiochem, Cambridge, MA). Antibodies used in this study
were purchased from following sources: anti-ubiquitin (P4D1),
anti-p27 (F-8), anti-GFP (B-2) (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-p21 Waf1/Cip1 (DCS60), anti-caspase3 (8G10),
anti-caspase8 (1C12), anti-caspase9 (C9), anti-PARP, anti-K48-
linkage specific polyubiquitin (D9D5), anti-phospho-histone
H2AX (Ser139) (20E3), anti-phospho-ATM (Ser1981) (D6H9),
anti-phospho-Chk1 (Ser345) (133D3), anti-phospho-Chk2 (Thr68)
(C13C1) (Cell Signaling Technology, Beverly, MA, USA); anti-
GAPDH, anti-HA-tag (Bioworld Technology, Inc., St. Louis Park,
MN, USA). Propidium iodide (PI) and Annexin V-FITC/PI apoptosis
detection Kit were purchased from Keygen Company (Nanjing,
China). 4,6-Diamidino-2-phenylindole (DAPI) was from Invitrogen
(Guangzhou, China). Enhanced chemiluminescence (ECL) reagents
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA).
2.4. Peptidase activity assay
Fluorogenic Suc-LLVY-AMC substrate was used to assay for
chymotrypsin-like activity of the 20S proteasome [15]. To assay
for in vivo proteasome inhibition, cancer cells were treated with
PtPT or bortezomib for 4 h. The cells were lysed in ice-cold lysis
buffer. Equal amounts of protein from each sample were then incu-
bated at 37 C with 50 lM fluorogenic substrate. To assay for direct
inhibition of the 20S proteasome in vitro, purified human 20S pro-
teasomes were incubated with the agent to be tested for 60 min at
37 C before the addition of the fluorogenic substrate. Fluorescence
intensity was measured using a spectrophotometer at excitation of
350 nm and emission of 438 nm (Varioskan Flash 3001, Thermo,
Waltham, MA, USA).
2.5. UV absorption spectra
The UV absorption spectra of fixed amounts of DNA in Tris–HCl
buffer solution were measured with addition of different concen-
trations of PtPT. The wavelength range of the system was from
200 to 600 nm. The blanks corresponding to the buffer were sub-
tracted to correct the absorbance at room temperature.
2.6. Fluorescence spectra
In order to determine the optimal molar ratio of ethidium bro-
mide (EB) to DNA, the fluorescence spectra of a fixed concentration
(8.25 lM) of EB were measured with varying the concentrations of
DNA from 0 to 57.75 lM. Then a 3.0 ml solution, containing a cer-
tain concentration of EB–DNA ([DNA]/[EB] = 7) complex solution,
was added to a 1.0 cm quartz cuvette and titrated by successive
addition of PtPT. These solutions were allowed to stand for 5 min
to equilibrate. The fluorescence spectra were measured at three
different temperatures (300, 305 and 310 K) in the wavelength
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The appropriate blanks corresponding to the buffer solution were
subtracted to correct the background.
2.7. Cell viability assay
MTS assay (CellTiter 96Aqueous One Solution reagent; Pro-
mega, Shanghai, China) was used to test cell viability according
to previously reported [40]. Briefly, 1  105/ml cells in 100 ll were
treated with either vehicle or PtPT and other agents for 48 h. Three
hours before culture termination, 20 ll MTS was added to the
wells. The absorbance density was read on a 96-well plate reader
at wavelength 490 nm. IC50 values were calculated.
2.8. Cell death assay
Apoptosis was determined by flow cytometry using Annexin V-
fluoroisothiocyanate (FITC)/propidium iodide (PI) double staining.
Cells were incubated with NiPT, then collected and washed with
binding buffer, then incubated in working solution (100 ll binding
buffer with 0.3 ll Annexin V-FITC) for 15 min in dark. Cells were
washed and resuspended with binding buffer. PI was added just
before flow cytometric analysis. Annexin V/PI staining was also
performed as described but in situ. The double stained cells were
also imaged with an inverted fluorescence microscope equipped
with a digital camera (Axio Observer Z1, Zeiss, Germany). To mon-
itor temporal changes in the incidence of cell death in the live cul-
ture condition, PI was added to the cell culture medium, and at the
desired sequential time points, the cells in the culture dish were
imaged with an inverted fluorescence microscope.
2.9. Computational modeling
To predict the binding of PtPT toward the DUBs (USP14 and
UCHL5), molecular docking studies were performed with CDOCKER
protocol of Discovery Studio 2.0 [Accelrys Software Inc. (2007)] as
we reported previously [16]. The crystallographic structures of
USP14 and UCHL5 were directly downloaded from the Protein Data
Bank (PDB IDs: 2AYO and 3RIS). After removing irrelevant compo-
nents, hydrogen atoms were added and their positions were min-
imized with a 0.01 kcal/mol/Å root mean square gradient by
using the all-atom CHARMm forcefield and the Adopted Basis
Newton–Raphson (NR) Algorithm. In addition, taking into account
the possible hydrolysis of compound PtPT (L1) in certain physio-
logical conditions, the hydrolysate (L2) was selected as the docking
ligand. The geometry structure of compound L2 was optimized
using the DFT calculations at the B3LYP/LANL2DZ level to obtain
NPA charges by using the Gaussian 03 [Revision D.01, Gaussian,
Inc., Wallingford, CT (2004)]. During the whole docking process,
the two proteins were rigid, while the ligand L2 was flexible. The
Input Site Spheres of 12 Å radius were centered on each active
pocket of USP14 and UCHL5, with (x, y, z) = (38.12, 84.32, 6.61)
and (9.40, 6.57, 61.54), respectively. The conformation corre-
sponding to the lowest CDOCKER Interaction Energy was selected
as the most probable binding conformation. All parameters used
in calculation were default except for those explained.
2.10. Western blot analysis
Whole cell lysates were prepared in RIPA buffer (1 PBS, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with
10 mM b-glycerophosphate, 1 mM sodium orthovanadate, 10 mM
NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 Roche
Complete Mini Protease Inhibitor Cocktail (Roche, Indianapolis,
IN, USA). Western blotting was performed as previously described
[17]. In brief, equal amounts of total protein extracts from culturedcells were fractionated by 12% SDS–PAGE and electrically trans-
ferred onto polyvinylidene difluoride (PVDF) membranes. Primary
antibodies and appropriate horseradish peroxidase-conjugated
secondary antibodies were used to detect the designated proteins.
The bounded secondary antibodies on the PVDF membrane were
reacted to the ECL detection reagents (Santa Cruz, CA) and exposed
to X-ray films (Kodak, Rochester, NY, USA).2.11. Nude mouse xenograft model
All animal protocols used were approved by the Institutional
Animal Care and Use Committee of Guangzhou Medical University.
The mice were obtained from Guangdong Laboratory Animal Mon-
itoring Institute (SCXK2008-2002). The nude BALB/c mice (male,
18–22 g) were housed in barrier facilities with a 12 h light dark
cycle, with food and water available ad libitum. 1–10  106 of
K562 or A549 cells was inoculated subcutaneously on the flanks
of 5-week-old male nude mice. After 72 h of inoculation, mice were
treated with either vehicle (10% DMSO, 30% polythylene glycol 400
and 60% 0.9% NaCl) or PtPT (5 mg/kg/day) for totally 15 days
(7 intervals), respectively. Tumor volumes were recorded and cal-
culated as previously reported [18].2.12. Immunofluorescence staining
Immunofluorescence staining was performed as reported [18].
Briefly, cell culture was performed on cover-slips in six-well plates
and allowed to grow overnight. After PtPT or CDDP treatment, the
cells were washed with PBS, fixed in 20 C for 5 min with 4%
paraformaldehyde, washed again in 0.2% Triton X100/PBS for
3  5 min and permeabilized with 1% TritonX100/PBS for 5 min.
Cells were blocked with 5% bovine serum albumin (BSA)/PBS for
1 h and subsequently exposed with primary antibodies, followed
by incubation with FITC-conjugated goat anti-rabbit IgG antibody
(Pierce Biotechnology). Cell nuclei were counterstained with DAPI
for 10 min. Samples were analyzed using a confocal laser micro-
scope (Zeiss LSM510 Meta, Germany). All images were acquired
under identical settings with LSM Image browser software.2.13. Immunohistochemical staining
Formalin-fixed xenografts were embedded in paraffin and sec-
tioned according to standard techniques as we previously reported
[19]. Tumor xenograft sections (4 lm) were immunostained using
the MaxVision kit (Maixin Biol, Fuzhou, Fujian, China) according to
the manufacturer’s instructions. The primary antibodies were used
as indicated. Fifty microliter MaxVisionTM reagent was applied to
each slide. Color was developed with 0.05% diaminobenzidine
and 0.03% H2O2 in 50 mM Tris–HCl (pH 7.6), and the slides were
counterstained with hematoxylin. A negative control for every
antibody was also included for each xenograft specimen by substi-
tuting the primary antibody with preimmune rabbit serum.2.14. DUB activity assay
This was performed as reported [16]. Briefly, cell lysate (5 lg) or
26S proteasomes (25 nM) were dissolved in ice-cold DUB buffer
containing 50 mM Tris–HCl (pH 7.4), 20 mM NaCl, 5 mM MgCl2
and 200 lMATP, and pretreated with PtPT or NEM for 15 min, then
incubated with Ub-AMC substrate in a 100 ll reaction volume at
25 C. Free AMC generated from substrate cleavage was temporally
recorded with a microplate reader (Varioskan Flash 3001, Thermo,
USA).
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In vitro disassembly of purified polyubiquitin chains (K48-
linked) was performed as described earlier. Purified 26S protea-
somes (25 nM) were pre-incubated with either vehicle or PtPT
for 10 min in vitro, and then K48-linked chains (500 ng) were
added into the reaction DUB buffer for 30 min at 37 C. The extent
of chain disassembly was assessed by western blot.
2.16. Active-site-directed labeling assays
Purified 26S proteasomes (25 nM) were dissolved in DUB buffer
(25 mM Tris–HCl pH 7.4, 5 mM MgCl, 20 mM NaCl, 200 lM ATP),
then treated with PtPT (5, 50 lM) for 10 min before they were
incubated with HA-UbVS for 1 h at 37 C, followed by boiling in
the reducing sample buffer and fractionated with SDS–PAGE. After
transferring to PVDF membranes, HA-UbVS labeled DUBs were
immunodetected using an HA antibody.
2.17. Detection of serum urea nitrogen (BUN) and creatinine
Blood samples were obtained by cardiac puncture on the day of
euthanasia. Serum levels of blood urea nitrogen (BUN) and crea-
tinine were measured using an automatic chemistry analyzer at
the Guangzhou First Municipal People’s Hospital, Guangzhou Med-
ical University.
2.18. Statistical analysis
All the results were expressed as Mean ± SD where applicable.
GraphPad Prism 4.0 software (GraphPad Software) was used for
statistical analysis. Student’s t test was used to compare the differ-
ences between variables. P value of <0.05 was considered statisti-
cally significant.3. Results
3.1. PtPT dose not directly bind DNA or induce DNA damage in vitro
and in vivo
First, UV absorption spectroscopy was employed to determine if
PtPT binds to DNA. When compounds bind to DNA, the absorption
spectroscopy shows hyperchromism (red shift) and hypochromism
(blue shift), which respectively originate from the breakage of the
DNA duplex secondary structure and the stabilization of the DNA
duplex by either the intercalation binding or the electrostatic effect
[20]. Because the intercalation involves a strong stacking interac-
tion between an aromatic chromophore and the base pairs of
DNA, the intercalation interaction is a common way of binding
between compounds and DNA [21]. The absorption spectra of PtPT
with increasing concentrations of calf thymus DNA are shown in
Fig. 1A; apparently no shift was found at the 300–500 nm, the
characteristic absorption band of PtPT. This indicates that DNA is
not changed after incubation with PtPT, suggesting that PtPT does
not directly bind to DNA.
To further confirm this, we next used fluorescence spectroscopy
to examine the impact of PtPT on DNA intercalation of EB. In a pre-
vious study, EB was shown to emit intense fluorescence light in the
presence of DNA, due to its strong intercalation between the DNA
base pairs, while the fluorescent light could be quenched by the
addition of a second molecule that binds to the DNA [22]. The
extent of fluorescence quenching can reflect the extent of binding
between the second molecule and DNA. The fluorescence emission
spectra of EB bound DNA in the absence and the presence of PtPT
are given in Fig. 1B. The addition of PtPT to DNA pretreated withEB did not cause appreciable reduction in the emission intensity,
indicating that there was no replacement of the EB fluorophore
by PtPT and no direct binding between PtPT and the DNA.
To study whether PtPT could induce DNA damage in cultured
cells, we utilized c-H2AX as a hallmark of DNA damage response
[23]. We monitored the c-H2AX level of A549 cells treated with
CDDP (2.5 lM) or PtPT (2.5 lM) using immunofluorescence. The
result showed typical formation of c-H2AX foci after treatment
of CDDP but not after PtPT treatment (Fig. 1C), indicating that PtPT
does not induce DNA damage in the cancer cells.
To investigate whether PtPT could interfere with the DNA dam-
age response pathway, the dose–response and the time course of
the expression of DNA damage-related proteins were detected in
A549 and K562 cells. We found that CDDP strongly induced the
expression of DNA damage-related proteins including c-H2AX, p-
ATM, p-chk2, and p-chk1 in both a dose- and a time-dependent
manner but PtPT did not except the p-ATM in K562 cells
(Fig. 1D and E). The same results were observed in non-
transformed normal cells but for the p-ATM in 16HBE cells
(Fig. 1F). To further test whether PtPT is a DNA damage-inducer
in vivo, nude mice bearing A549 xenograft were injected with PtPT
(5 mg/kg every day, i.p.) or CDDP (2.5 mg/kg every other day).
Immunoblotting analyses showed that c-H2AX was increased in
liver and kidney tissues with CDDP treatment but not with PtPT
(Fig. 1G), indicating that PtPT does not induce DNA damage in
mice. Collectively, these results suggest that PtPT does not induce
DNA damages.
Interestingly, we found that CdPT, a cadmium complex of pyr-
ithione, induced the expression of DNA damage-related proteins,
such as c-H2AX, p-ATM p-chk2, and p-chk1 in cultured cells and
of c-H2AX more strongly in kidney tissue than cisplatin (Fig. 2),
exhibiting a property different from PtPT.
3.2. PtPT inhibits proteasome function in cultured cancer cells
Recently we have reported that CuPT, a cooper pyrithione com-
plex, could remarkably inhibit proteasome function [24]. To test
whether PtPT is able to inhibit proteasome function as a pyrithione
complex, we first measured the levels of ubiquitinated proteins in
A549, A549/DDP and K562 cells incubated with PtPT, bortezomib/
Velcade, CDDP, or b-AP15. As expected, PtPT induced marked
increases in both total and the K48-linked ubiquitinated proteins
as well as in proteasome substrate p27 (Fig. 3A and B). Addition-
ally, PtPT was also able to accumulate a surrogate proteasome sub-
strate (GFPu) and total ubiquitinated proteins (Ub-prs) in a stable
GFPu-HEK293 cell line (Fig. 3C and D). PtPT at 5.0 lM induced
Ub-prs accumulation as strongly as Velcade at 50 nM did in these
cells, and better than 0.5 lM b-AP15, a reported DUBs inhibitor
(Fig. 3A). By contrast, CDDP failed to inhibit proteasome function,
even at much higher doses compared with PtPT (Fig. 3A). These
results suggest that PtPT can inhibit ubiquitin-mediated protein
degradation. To elucidate the molecular mechanism of this action,
we first tested the direct effect of PtPT on proteasome peptidase
activities. We found that PtPT caused no decline of proteasome
chymotrypsin-like (CT-like) activities in either purified 20S protea-
somes or cultured cells, whereas Velcade substantially inhibited
the proteasome activity in both assays (Fig. 4). These results sug-
gest that PtPT does not directly block 20S proteasome peptidase
activity.
3.3. PtPT inhibits the UPS by targeting DUBs USP14 and UCHL5
associated with 26S proteasomes
In general, the 26S proteasome is primarily responsible for the
degradation of ubiquitinated proteins. The 26S is formed by the
20S proteasome capped by the 19S regulatory particle (RP) at
Fig. 1. PtPT dose not induce DNA damage in vitro and in vivo. (A) UV absorption spectra of PtPT (8.96  106 M)with various concentrations of DNA [0 (a), 1.42 (b), 2.85 (c), 4.27
(d)  105 M]. (B) Fluorescence spectra of DNA-EB with various concentrations of PtPT. c(EB) = 2 lM; c(DNA) = 1.4  105 M, c(PtPT) = [1.2 (A), 3.1 (B), 6.4 (C)  105 M]. (C)
Immunostaining of c-H2AX at different times after exposure to CDDP or PtPT. A549 cells were treated with CDDP (2.5 lM) or PtPT (2.5 lM) for indicated times, followed by
immunofluorescence staining assay. Green: c-H2AX, blue: nuclei stainedwith DAPI (scale bar, 50 lm). (D–F) DNA damage-related protein expression. Cancer cells (A549/K562)
and non-transformed normal cells (16HBE/LO2) were incubated with PtPT or CDDP to detect dose- and time-dependent effects. DNA damage-related proteins including c-
H2AX, p-ATM, p-chk2, p-chk1 and PARP were detected by western blot. (G) DNA damage response in mouse tissue. Nudemice bearing A549 xenograft were injected with PtPT
(5 mg/kg/day, i.p.) or CDDP (2.5 mg/kg/2 day), liver and kidney tissues were collected for western blots for c-H2AX. One representative blot (D/E/F/G, upper panel) out of three
independent experiments is shown and quantified by densitometric analysis (lower panel). Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each control.
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Fig. 2. CdPT induces DNA damage in vitro and in vivo. (A) CdPT induces DNA damage responses. Cancer cells (A549/K562) were incubated with various doses of CdPT or CDDP,
DNA damage-related proteins including c-H2AX, p-ATM, p-chk2, p-chk1 and PARP were analyzed by western blot. (B) DNA damage in mouse tissues. Nude mice bearing A549
xenograft were i.p. injected with CdPT (5 mg/kg/2 day) or CDDP (2.5 mg/kg/day), liver and kidney tissues were collected for western blots for c-H2AX. One representative blot
(A/B, upper panel) out of three independent experiments is shown and quantified by densitometric analysis (lower panel). Values are expressed as mean ± SD (n = 3). *P < 0.05,
compared with each control.
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reside in the 20S. In the 26S proteasome, the 19S RP functions to
engage ubiquitinated protein substrates, deubiquitinate the sub-
strate, and unfold the substrate proteins before being channeled
into the 20S proteolytic chamber. Given that PtPT inhibits protea-
some function independently of the 20S, we hypothesized that
PtPT may indirectly inhibit the proteasome via targeting the DUB
activity of the 26S. The proteasome DUB activity is mainly attribu-
ted to the action of RPN11, USP14 and UCHL5 located in or associ-
ated with the 19S RP. We first assessed the effect of PtPT on the
total DUB activities of cell lysates using a fluorogenic substrate
Ub-AMC. Treatment with NEM (a general inhibitor of cysteine pro-
teases) completely blocked the total DUB activities, but we did not
detect any remarkable change in PtPT- or CDDP-treated groups
(Fig. 5A); similarly, PtPT did not show remarkable effect on a panel
of recombinant non-proteasomal DUBs (Fig. 5B). Next, we mea-
sured the DUB activity in purified 26S proteasomes co-treated with
PtPT (5.0 lM). PtPT treatment exhibited complete inhibition of
26S-associated DUB activity (Fig. 5C). In addition, a dose–response
test revealed that PtPT could inhibit the 26S-associated DUB activ-
ity in a dose-dependent fashion (Fig. 5D). Notably, CDDP did not
show any effect on 26S-associated DUB activity (Fig. 5D). To fur-
ther confirm this pharmacological action, we examined the effect
of PtPT treatment on in vitro disassembly of purified tetraubiquitin
chains (Ub4) by the 26S proteasome. K48-linked Ub chains were
disassembled in the presence of 26S proteasomes and this action
was attenuated by PtPT in a dose-dependent manner (Fig. 5E).
These experiments demonstrate that PtPT inhibits 26S-associated
DUBs selectively rather than acting broadly on all DUBs in the cell.
To identify which proteasome-associated DUBs can be inhibited
by PtPT, we first performed computational docking study to predict
the binding information between PtPT and 26S-associated DUBs
including USP14 and UCHL5. The chemical structures of PtPT (L1)and its metabolized product (L2), a hydrolysate of PtPT, are shown
in Fig. 5F. Previous studies revealed that the catalytic core in the
active site of USP14 is formed by Cys113, His434 and Asp450
[25], and that of UCHL5 is formed by Cys88, His164 and Asp179
[26]. The docking analyses predict that PtPT could bind to the
active sites of USP14 and UCHL5, with CDOCKER Interaction Energy
of 15.99 and 16.78 kcal mol1, and the binding modes are dis-
played in Fig. 5F. In the binding site of USP14, the S atom of
Cys113 coordinates to Pt2+ with distances of 2.939 Å. In addition,
one hydrogen bond of 2.483 Å is formed between the polar H of
Cys113 and the O atom of PtPT. In the binding site of UCHL5, there
are two coordination bonds between the Pt2+ and two side chains,
His164 and Phe165, with corresponding bond lengths of 3.350 and
2.550 Å. At the same time, the S atom of PtPT forms two hydrogen
bonds with Cys88 and Gln91 (2.140 and 1.194 Å). These calculation
results suggest that PtPT can bind to the catalytic cores of USP14
and UCHL5 through coordination bonds and hydrogen bonds. To
confirm the computational docking results, we performed compet-
itive labeling experiments using HA tagged ubiquitin vinyl-
sulphonone (HA-UbVS), an active site probe of cysteine DUBs.
Incubation of PtPT with 26S proteasomes abolished UbVS binding
with either UCHL5 or USP14 in a dose-dependent manner (Fig. 5G).
These computational and experimental results indicate that PtPT
can selectively target UCHL5 and USP14, two proteasome-
associated DUBs.
3.4. PtPT induces cytotoxicity in cultured cancer cells
Previous reports have shown up-regulation of proteasome
activities in many different types of cancers, such as colon and
prostate cancers as well as leukemia [27–29], suggesting that can-
cer cells may depend more upon the UPS for survival and growth
than non-cancer cells. Therefore, we examined whether inhibition
Fig. 3. PtPT inhibits proteasome function in multiple cancer cells. (A and B) Dose-dependent accumulation of proteasomal substrates in K562, A549 and A549/DDP cells.
These cells were treated with PtPT (2.5, 5, 7.5, 10 lM), bortezomib/Velcade (Vel, 50 nM), CDDP (20 lM), or b-AP15 (0.5 lM) for 12 h, followed by detecting the levels of total
(Ub-prs) and K48-linked (K48-) ubiquitin conjugates, p27, and PARP cleavage with western blot analysis. (C and D) The changes of a surrogate proteasome substrate (GFPu).
HEK-293 cells stably expressing GFPu were treated with PtPT for 12 h, then ubiquitinated proteins and GFPu protein were detected with western blot or imaged under an
inverted fluorescence microscope (scale bar, 50 lm). Bortezomib/Velcade (Vel) and b-AP15 were used as positive controls. CDDP was used as a negative control. One
representative blot (A/B/D, upper panel) out of three independent experiments is shown and quantified by densitometric analysis (lower panel). Values are expressed as
mean ± SD (n = 3). *P < 0.05, compared with each control.
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induce cytotoxicity in a panel of cancer cells (K562, U266, A549,
SMMC-7721, A549/DDP). These experiments also included cis-
platin (CDDP) for comparison. We first investigated the effect of
PtPT and CDDP on these cultured cells using MTS assay, our results
indicated that exposure to increasing doses of PtPT over a period of
48 h decreased the viability of these cancer cells in a dose-
dependent fashion and showed better efficacy than CDDP, except
for cisplatin-sensitive cells A549 to which PtPT and CDDP showed
comparable efficacy (Fig. 6A–E). Importantly, we found that PtPTcould partially overcome the CDDP resistance of A549/DDP cells
(Fig. 6C). It was important to note that viability inhibition of PtPT
at a dose up to 5 lM toward non-transformed normal cells (e.g.,
LO2, 16HBE) (Fig. 6F and G) was much less than that toward cancer
cells; however, this selective inhibition was not observed from cis-
platin. We next analyzed the capacity of PtPT to induce cell death
in cisplatin-sensitive cell line. A549 cells were exposed to PtPT for
either 24 or 36 h, followed by recording the PI (propidium iodide)-
positive cells with fluorescence microscopy. We observed that PtPT
induced a dose-dependent cell death started as early as 24 h while
Fig. 4. PtPT does not inhibit 20S proteasome peptidase activities in vitro. (A) The effect of PtPT on 20S proteasome peptidase activities in vitro. 20S proteasomes were treated
with different doses of PtPT or CDDP; and Chymotrypin-like activity was measured using specific synthetic fluorogenic substrate. Bortezomib/Velcade (Vel) was used as a
positive control. (B–D) The in situ effect of PtPT on proteasome peptidase activity. K562 (B), A549 (C) and A549/DDP (D) cells were treated with increasing doses of PtPT or
CDDP for 6 h, and Chymotrypsin-like activity was assayed. Bortezomib/Velcade (Vel) was used as a positive control. n = 3, mean ± SD. *P < 0.05, compared with each control.
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thermore, PtPT-induced apoptosis is shown in Fig. 6I and J. A549
and K562 cells were treated with the indicated dose of PtPT and
CDDP for 24 h, apoptotic cells were detected by flow cytometry
with Annexin V/PI staining. The results revealed that PtPT could
dose-dependently induce cell apoptosis more effectively than
CDDP. Taken together, these findings suggest that the selectivity
profile and effectiveness of PtPT to kill cancer cells in vitro are bet-
ter than those of CDDP which is currently licensed for clinical use.
3.5. PtPT-induced apoptosis is associated with caspase activation
To test whether the cytotoxicity of lung adenocarcinoma cancer
cell lines following PtPT treatment is associated with caspase acti-
vation, the amplitude of mitochondrial membrane potential
(MMP) disruption was assessed after PtPT treatment by flow
cytometry in A549 and A549/DDP cells. The data showed that PtPT
induced a dose-dependent loss of MMP in the cells (Fig. 7A), sug-
gesting that an apoptosis-inducing mechanism is triggered by PtPT
treatment. Fig. 7B shows the dose-dependent release of cyto-
chrome c and AIF from mitochondria into cytosol after being
exposed to PtPT for 12 h. To further investigate the mechanism
of PtPT-induced apoptosis, the activation of the caspase cascade
was investigated. A549 and A549/DDP were incubated with PtPT,
followed by western blot analysis. The results showed that the
induction of cleaved PARP by PtPT treatment paralleled the
increase of the active forms of caspases-3 in a dose- and time-
dependent pattern, and the cleavage of procaspase-9 was induced
concomitantly with that of procaspase-3, -8 in a similar pattern to
PARP cleavage (Fig. 7C). Collectively, these results indicate that
PtPT triggers lung adenocarcinoma cancer cell apoptosis via cas-
pase activation.
3.6. Proteasome inhibition is required for PtPT to induce apoptosis
If inhibition of the proteasome is responsible for induction of
apoptosis, inhibition of proteasome should occur prior to cell
death. To test this hypothesis, we determined the time course of
PtPT-induced proteasome inhibition. A549, A549/DDP and K562
cells were treated with either vehicle or 2.5 lM of PtPT for 6, 12,
18, 24 h, followed by detection of total, K48-linked ubiquitinatedproteins and proteasome substrate p27 using western blot analy-
ses. We found that accumulation of ubiquitinated proteins was
observed during the course of treatment as early as 6 h
(Fig. 8A and B). Accumulation of p27 was also found to be time
dependent. Importantly, apoptosis-specific PARP cleavage was
not observed until 12 h of PtPT treatment (Fig. 8A and B). These
results show that the apoptosis induced by PtPT occurs after the
proteasome inhibition. Next, we tested the effect of EDTA
(ethylenediaminetetraacetic acid), a chelating agent for metal ions
such as Pt2+, on the PtPT induction of proteasome inhibition and
cell death. Fig. 8C shows that PtPT exhibited diminished reactivity
after being bound by EDTA. As expected, EDTA partially reversed
PtPT-induced ubiquitinated protein accumulation; and PARP cleav-
age (indicators of apoptosis) was accordingly abolished in A549
cells (Fig. 8D). This diminished effect on cell death was also con-
firmed using propidium (PI) staining followed by inverted fluores-
cent microscopy (Fig. 8E). Therefore, proteasome inhibition is
required for apoptosis induction by PtPT.
3.7. PtPT specifically induces cytotoxicity and proteasome inhibition in
cancer cells from leukemia patients
To further evaluate the antineoplastic effects of PtPT, bone mar-
row cells from six leukemia patients were treated ex vivo with
increasing doses of PtPT. Peripheral blood mononuclear cells
(PBMCs) from 6 healthy volunteers were used as controls. We
found that the average IC50 values for PtPT in normal PBMCs were
about 4.413 ± 0.392 lM, approximately 6 times higher than that
for primary monocytes obtained from leukemia patients
(0.754 ± 0.102 lM) (Fig. 9A). In contrast, the IC50 values of cis-
platin for the two types of cells were similar; and importantly,
the IC50 of cisplatin for leukemia cells was much higher than that
of PtPT (Fig. 9B). Additionally, the difference in the IC50 values of
bortezomib toward the normal and leukemia monocytes was not
as dramatic as those of PtPT (Fig. 9C). PtPT treatment for 24 h at
doses ranging from 0.25 to 1.0 lM resulted in significant apoptosis
in the monocytes from leukemia patients as detected with Annexin
V/PI staining by flow cytometry (Fig. 9D) or by fluorescence micro-
scope (Fig. 9E). Treatment with PtPT significantly increased the
level of Ub-prs and cleaved PARP in cancer cells from AML patients
(Fig. 9F). In contrast, CDDP failed to induce marked cell death and
Fig. 5. PtPT inhibits proteasomal deubiquitinase (DUB) USP14 and UCHL5. (A) The effect of PtPT on cytoplasmic total DUB activities. A549 cell lysates were exposed to PtPT
(5.0 lM) and dynamic DUB activity was measured. NEM was used as a positive control. (B) The effect of PtPT at the indicated dosages on the activity of 5 recombinant non-
proteasomal deubiquitinases (UCHL1, UCHL2, BAP1, USP5, and USP7) was tested. End-point DUB activity is shown. n = 3, Mean ± SD. (C) The effect of PtPT on proteasomal DUB
activities. Purified 26S proteasomes were incubated with PtPT or CDDP (5.0 lM), and then DUB activity kinetics were measured. NEM was used as a positive control. (D)
Purified 26S proteasomes were treated with PtPT (0.5, 1.0, 2.0 lM), then dynamic DUB activity was recorded. (E) Ubiquitin chain disassembly assay. The disassembly of K48-
linked ubiquitin tetramers mediated by the 26S proteasome was detected in the presence of PtPT or b-AP15.One representative blot (E/left panel) out of three independent
experiments is shown and quantified by densitometric analysis (E/right panel). Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each Ub4. (F)
Computational molecular docking of PtPT with UCHL5 and USP14 of the 26S proteasomes. The following data are shown: the structure of platinum pyrithione (L1); the
structure of platinum pyrithione intermediate (L2); the binding modes of compound L2 at the active site of USP14; the binding models of compound L2 at the active site of
UCHL5. (G) Active-site-directed labeling of proteasomal DUBs. Purified 26S proteasomes were treated with PtPT, NEM, or b-AP15, followed by labeling with HA-UbVS and
immunoblotting for HA. One representative blot (E/left panel and G/upper panel) out of three independent experiments is shown and quantified by densitometric analysis (E/
right panel and G/lower panel). Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each 26S.
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(Fig. 9E and F). Nonetheless, PtPT treatment at 5 lM started to
cause detectable cell death in monocytes from healthy volunteers(Fig. 9G). These results clearly demonstrate that PtPT specifically
induces ex vivo proteasome inhibition and cytotoxicity in primary
human cancer cells.
Fig. 6. PtPT induces cytotoxicity in cultured cancer cells. (A–E) Cytotoxic curves in U266 (A), K562 (B), A549/DDP (C), A549 (D), SMMC-7721 (E) cells treated with increasing
doses of PtPT or CDDP for 48 h. The cell viability was detected by MTS assay. Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each CDDP. (F and G) LO2 (F)
and 16HBE (G) cells were treated with escalating doses of PtPT or CDDP for 48 h, and cell viability was then detected by MTS assay. Values are expressed as mean ± SD (n = 3).
*P < 0.05, compared with each CDDP. (H) PtPT induced cell death in A549 cells. A549 cells were treated with the indicated doses of PtPT or CDDP (5 lM), then PI was added to
the cultured cells after 24 h treatment, and PI-positive staining was monitored under an inverted microscope and typical images are shown. (I and J) Apoptosis induction by
PtPT in A549 and K562 cells. A549 and K562 cells were treated with the indicated doses of PtPT or CDDP (5 lM) for 24 h, apoptotic cells were detected with Annexin V–PI
staining followed by flow cytometry.
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We next evaluated the effect of PtPT on tumor growth in vivo
using nude mouse xenograft models. PtPT was administered to
BALB/c nude mice bearing A549 and K562 xenografts, the tumor
size curves and images showed a significant reduction of tumorburden in mice treated with PtPT versus the control group
(Fig. 10A and B, J and K). Consistent with the reduction in tumor
growth, PtPT-treated mice also showed a reduction in tumor
weight (Fig. 10C and L). Importantly, we observed no change in
mouse behavior or loss in body weight (Fig. 10D and M). In the
A549 xenograft model, we used CDDP as a positive control. In
Fig. 7. PtPT-induced apoptosis is associated with caspase activation. (A) PtPT induces down-regulation of mitochondrial membrane potential in A549 and A549/DDP cells.
Cells were treated with the indicated dose of PtPT for 12 h, mitochondrial membrane potential was detected by rhodamine-123 staining followed by flow cytometry.
Quantified analysis is given right. Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each control. (B) PtPT induces cytochrome C and AIF release. A549 and
A549/DDP cells were exposed to different doses of PtPT for 12 h, then cell cytoplasm were extracted by digitonin buffer and the released AIF and cytochrome C were detected
by immunoblotting analysis. (C) PtPT induces cleavage of PARP, caspase-3, -8, -9 in A549 and A549/DDP cells. A549 and A549/DDP cells were treated with PtPT at various
doses or for various times, PARP, and caspase-3, -8, -9 cleavage were analyzed by immunoblotting. GAPDH was detected as a loading control. One representative blot (B/left
panel and C/upper panel) out of three independent experiments is shown and quantified by densitometric analysis (B/right panel and C/lower panel). Values are expressed as
mean ± SD (n = 3). *P < 0.05, compared with each control.
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effective antitumor activity but an obvious reduction of body
weight was also detected (Fig. 10D). We also test the content of
AST and ALT (two indicators of liver function) in mouse serum.
We found that CDDP treatment induced dramatic increases of
these two enzymes in the serum but PtPT did not (Fig. 10E). To
assess nephrotoxicity in mouse treated with PtPT, we comparedthe acute kidney injury (AKI) of PtPT and CDDP by intraperitoneal
(ip) injection of a single dose of 15 mg/kg respectively in nude
mice, and found that CDDP-treated group showed significant renal
impairment, as indicated by significantly increased levels of serum
urea nitrogen (BUN) and creatinine as well as marked histologic
damage in animals at day 4 after CDDP application (Fig. 10F–H).
Conversely, there were not any detectable changes in either
Fig. 8. Proteasome inhibition is required for PtPT to induce apoptosis. (A and B) PtPT time-dependently induces proteasome function inhibition and apoptosis in cancer cells
(A549, A549/DDP and K562). The cells in culture treated with PtPT (5 lM) were collected at the indicated time points for western blot analyses for ubiquitinated proteins
including total ubiquitin conjugates (Ub-prs) and K48-linked polyubiquitins, p27, as well as cleaved PARP. (C) An illustration of the coordination of Pt with
ethylenediaminetetraacetic acid (EDTA) to inactivate PtPT. (D and E) EDTA prevented most PtPT-induced proteasome inhibition and apoptosis. A549 cells were treated with
PtPT with/without chelating agent EDTA (100 lM) for 12 h, total ubiquitin conjugates and PARP were detected with western blot analysis, and apoptosis cells were recorded
with PI staining followed by imaging under fluorescence microscopy. One representative blot (A/B/D, upper panel) out of three independent experiments is shown and
quantified by densitometric analysis (lower panel). Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each control.
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group (Fig. 1F–H). The immunostaining analysis was performed
to detect the effect of PtPT on in vivo proteasome function. The
results showed that highly increased levels of proteasome sub-
strates including total and K48-linked ubiquitinated proteins were
observed in the PtPT-treated tumor tissues, accompanied by
caspase-3 activation (Fig. 10I and N). Hence, in contrast to CDDP,
PtPT could selectively inhibit in vivo tumor growth without appar-ent non-specific toxicity, with a distinct mechanism involving pro-
teasome inhibition.4. Discussion
By targeting DNA, platinum-based drugs, as exemplified by cis-
platin, are a giant pillar in current clinical cancer chemotherapy;
Fig. 9. PtPT specifically induces cytotoxicity and proteasome inhibition in cancer cells from leukemia patients. (A–C) Cancer cells from 6 leukemia patients (Pt) and peripheral
blood mononuclear cells from 6 healthy volunteers (Nm) were treated with PtPT at the indicated doses or with CDDP or Velcade (Vel) for 48 h, then the cell viability was
detected by MTS assay. The scatter plots of the IC50 values of PtPT (A) and CDDP (B) in each group are shown. Cell viability with Vel treatment in each group is also shown (C).
n = 3, Mean ± SD. *P < 0.05, **P < 0.01, compared with each control. (D) Cancer cells from patients were treated with increasing doses of PtPT for 24 h. Typical cell apoptosis
from one sample (#2) was analyzed by flow cytometry and shown. Quantified analysis is given right. Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each
control. (E) Cancer cells from patients were incubated with PtPT at the indicated doses or with CDDP (10 lM) or Vel (50 nM) for 24 h, then cells were stained with Annexin V/
PI and imaged under a fluorescent microscope (scale bar, 50 lm). Typical results from one sample (Patient #1) are shown. (F) Leukemia cells were incubated with PtPT at the
indicated doses or with CDDP (10 lM) or Vel (50 nM) for 24 h, then ubiquitinated proteins and PARP were detected by western blot. Representative results from one sample
(patient #2) are shown. One representative blot (F/upper panel) out of three independent experiments is shown and quantified by densitometric analysis (lower panel).
Values are expressed as mean ± SD (n = 3). *P < 0.05, compared with each control. (G) The peripheral mononuclear cells from normal human individuals were incubated with
PtPT at the indicated doses or with CDDP (10 lM) or Vel (50 nM) for 24 h, then cells were stained with Annexin V/PI and imaged under a fluorescent microscope (scale bar,
50 lm). Representative images are shown.
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to the DNA targeting by this drug family are major problems lim-
iting their clinical use and efficacy. Hence, search for more tolera-
ble and effective alternatives for cisplatin is imperative. To this
end, the present study represents a very exciting breakthrough
because we have identified a new platinum-based anti-cancer
agent (PtPT) which operates via selective inhibition of proteasomal
DUBs rather than indiscriminately targeting DNA. This target
switch endows PtPT with remarkably improved selectivity and
greater potency in killing cancers both in vitro and ex vivo, and witha much more favorable safety profile than cisplatin as revealed by
the preclinical in vivo trial using a tumor xenograft mouse model.
Chemical complexes containing metal ions, such as gallium (III),
copper (II), zinc (II), nickel (II), and cobalt (II), were designed to tar-
get the 26S proteasome in the past decade [30–33]. The discovery
that these metal-based complexes exert their antiproliferative
action by suppressing proteasomal proteolytic peptidase activities
provided a potentially new direction in developing new cancer
therapy. Although several essential or nonessential metals have
been reported to interfere with UPS function, platinum, a pioneer
Fig. 10. PtPT inhibits tumor growth and proteasome function in vivo. (A–D) BALB/c nude mice bearing A549 tumors were treated with vehicle or PtPT (5 mg/kg/day, i.p.) or
CDDP (2.5 mg/kg/2 day, i.p.) for 15 days. Tumor size was recorded every other day. Tumor size (A), tumor images (B), tumor weight (C) and body weight (D) are shown. n = 6,
mean ± SD. *P < 0.05, **P < 0.01, compared with each control. (E) Liver function was assessed by detecting serum AST and ALT. n = 6, mean ± SD. *P < 0.05, compared with each
control. AU, arbitrary unit. (F–H) BALB/c nude mice were treated with a single injection of vehicle, PtPT (15 mg/kg, i.p.) or CDDP (15 mg/kg/, i.p.), and sacrificed 4 days later.
The graph showing the serum BUN (F) and creatinine (G) levels in each group. *P < 0.05, compared to vehicle control (n = 6). Representative photomicrographs (200) of
mouse kidney sections with Periodic Acid Schiff staining are shown (H). (I) Representative immunohistochemical staining results are shown for total (Ub-prs) or K48-linked
ubiquitin accumulation, proteasome substrate protein (p21), and cleaved caspase-3 in A549 tumor tissues from nude mice treated with vehicle, PtPT, or CDDP (200). (J–M)
BALB/c nude mice bearing K562 tumors were treated with either vehicle or PtPT (7.5 mg/kg/day, i.p.) for consecutive 15 days, Tumor size was recorded every other day.
Tumor size (G), tumor images (H), tumor weight (I) and body weight (J) are shown. n = 6, mean ± SD. **P < 0.01, compared with each control. (N) Representative images of
immunohistochemical staining for total (Ub-prs), K48-linked ubiquitin accumulation, proteasome substrate protein (p27), and cleaved caspase-3 in tumor tissues from mice
bearing K562 tumors treated with either vehicle or PtPT (200).
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Fig. 11. A schematic illustration of the biotarget of a novel platinum complex PtPT.
Pt-based compounds target the different cellular components. CDDP but not PtPT
interacts with DNA via covalent binding to induce DNA damage; conversely, PtPT
but not CDDP targets proteasomal deubiquitinases. CDDP, cisplatin; PtPT, platinum
pyrithione.
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present study unveils for the first time that by complexing with
pyrithione, platinum no longer binds to DNA but targets effectively
the 26S proteasome-associated DUBs instead. This is compellingly
supported by a preponderance of in vitro and in vivo evidence
(Figs. 1–3). Previous work has shown that the platinum center of
cisplatin reacts with DNA, forming two covalent bonds to N7 atoms
of two adjacent guanine bases. Here our in vitro tests demonstrate
that, unlike cisplatin, PtPT does not bind DNA with a typical inter-
calative binding or covalent interaction. This has also been shown
by Vieites et al. using agarose gel electrophoresis [34]. Further-
more, our results obtained from immunofluorescence and western
blot analyses using c-H2AX as an indicator of DNA damage in cul-
tured cells and mice are in agreement with our conclusion dawn
from in vitro findings. Indeed no increased levels of DNA damage
markers such as p-ATM or c-H2AX were induced by PtPT treat-
ment, suggesting that PtPT is non-genotoxic; this is starkly differ-
ent from cisplatin. Through induction of DNA damage or genotoxic
stress, cisplatin led to a rapid activation of ATM and then phospho-
rylates Chk1 and Chk2 and H2AX in tumor cells. We also observed
increased expression of c-H2AX in the kidney and liver tissues of
cisplatin-, but not PtPT-, treated mice. This is of vital importance
because DNA damage in renal cells and tissues causes cisplatin
nephrotoxicity [35]. Moreover, we show that CdPT, a cadmium
complex of pyrithione, induces DNA damage response similarly
to cisplatin in vitro and more strongly in kidney than cisplatin,
exhibiting a property vastly different from PtPT. These results indi-
cate that the platinum metal ion is an important determinant of
the observed effects from PtPT. Notably, PtPT is also highly effec-
tive in inducing cytotoxicity in cisplatin-resistant cells, which is
not only consistent with the notion that PtPT does not act on
DNA damage-based biotargets but also suggests that PtPT can be
a promising drug candidate for overcoming cisplatin-resistance.
We also have provided multiple lines of evidence that PtPT
takes a mechanism distinct from the classical proteasome inhibitor
bortezomib to accumulate endogenous and surrogate proteasome
substrates. The extent of proteasome inhibition induced by PtPT
is comparable to bortezomib as reflected by their similar effects
on accumulation of both Ub-prs and GFPu. However, analyses of
computational docking and enzyme inhibition show that PtPT dis-
plays properties consistent with a mechanism of competitive inhi-
bition of 26S proteasome DUB activity. Recently, a series of
compounds including WP1130, AC17, b-AP15, and b-AP15-
derivative analogs (e.g., RA-9, VLX1570), which all contain a, b
unsaturated dienones (i.e., Michael acceptors), were reported to
inhibit proteasome DUBs [36–40]. All of these DUB inhibitors are
electrophiles and would be expected to confer nonspecific reactiv-
ity. Indeed, it was found that RA-9 inhibited in vitro UCHL1, UCHL3,
USP8 and USP9x, besides USP14 and UCHL5. WP1130 was also
found to inhibit a broader spectrum of DUBs. In our docking for
the bound PtPT models, we find the formation of coordination
and hydrogen bonds between Pt2+ and the specific amino acid resi-
due of USP14 and UCHL5, a reaction model distinct from Michael
reaction of a, b unsaturated dienones. This is experimentally con-
firmed by our comparison of the ability of PtPT to inhibit the pro-
teasomal and non-proteasomal DUBs. PtPT did not show
discernible effect on either overall cellular DUB activities or a panel
of recombinant non-proteasomal DUBs but remarkably inhibited
26S proteasome-associated DUB activity in a dose-dependent man-
ner. PtPT is also distinct from CuPT, a metal complex reported in
our previous work [24], which acts as both a broad-spectrum
DUB inhibitor and 20S proteasome peptidase inhibitor, inducing
highly toxic effects in vitro, in situ and in vivo. Collectively, these
results demonstrate that only PtPT but not other metal pyrithione
compounds tested so far (copper, cadmium) exerts proteasome
inhibition by selectively targeting proteasomal UCHL5 andUSP14. PtPT is also strikingly distinct from IU1, a USP14 inhibitor
reported previously [41], which inhibits USP14 but not UCHL5
activity and promotes the degradation of ubiquitinated proteins.
In summary, unlike cisplatin which targets DNA, PtPT targets
primarily proteasomal DUBs instead of DNA and exhibits better
anticancer effects than cisplatin (Fig. 11). The DNA-platination of
clinical Pt-based drugs rests in the coordination around the metal
ion of two non-leaving groups (N–Pt bonds) and of two fast-rate
leaving groups (i.e., chlorides). The rate of DNA-platination is mod-
ulated by the nature of the leaving groups. The presence of two
medium-rate leaving groups (i.e., pyrithione containing S and O
atom) allows them to react with protein targets even before PtPT
reaches the nucleus. Hence, the ligand pyrithione endows platinum
with the capacity to selectively target proteasomal DUBs.
Others have shown that cancer cells possess progressive up-
regulation of the metabolic machinery to sustain the increased
proliferation rate [42–44]. This phenomenon renders cancer cells
more sensitive to UPS inhibition. In this study, we showed that
inhibition of proteasome-associated DUBs by PtPT treatment selec-
tively suppressed the cell viability of multiple types of cancer cells
in cultures. Importantly, PtPT treatment caused marked reduction
in cell viability of A549 cells and their cisplatin-resistant parental
lines. Notably, PtPT selectively induced Ub-prs accumulation and
apoptosis in primary cancer cells from leukemia patients but much
less cell death in normal mononuclear cells than in cancer cells. On
the contrary, cisplatin as a genotoxic agent induces cytotoxicity in
normal cells similarly to the cancer cells. In addition to our in vitro
studies, we also examined anticancer activity of PtPT in vivo. Our
results showed that treatment of cancer xenografts with PtPT sig-
nificantly retarded tumor growth. Importantly, compared with cis-
platin, PtPT treatment was not associated with toxicity, including
reduction of body weight and liver function and perturbed renal
histology and function that are commonly seen in CDDP treatment.
These results strongly suggest that PtPT is a better anticancer can-
didate than cisplatin and could be used in the treatment of multi-
ple cancers. As expected, the chymotrypsin-like activity of tumor
tissues was not inhibited with PtPT treatment (data not shown),
while bortezomib could inhibit chymotrypsin-like activity in
tumor or other tissues as we previously reported [45], further con-
firming that PtPT inhibits the UPS in vivo via targeting proteasomal
DUBs.
C. Zhao et al. / Biochemical Pharmacology 116 (2016) 22–38 37Even though we could not completely exclude other binding
partners of PtPT, our in vitro and in vivo findings demonstrate that
targeting the proteasomal DUBs UCHL5 and USP14 is a major
mechanism for the selective anticancer activity of PtPT.
Competing financial interests
The authors declare that they have no competing commercial or
financial interests.
Funding
This work was supported by the National High Technology
Research and Development Program of China (2006AA02Z4B5);
NSFC (81272451/H1609, 81472762/H1609); Key Projects
(10A057S) from Guangzhou Education Commission and a project
(2010A060801016) from Guangdong Key Laboratory of Urology
(to J.L.); NSFC (81201719/H1609) (to H.H.) and in part by US NIH
grants HL072166 and HL085629 (to X.W.).
Author contributions
J.L., C.Z. and X.W. designed experiments; C.Z., X.C., D.Z., X. Lan, C.
Y., J. Wu, Y. Liao, H.H., L.J., X.S., and X.L. performed experiments; S.
Liao and P.Z performed computational docking; X. Li and L.N. pro-
vided clinical samples; J.L. and X.W. wrote the manuscript. All
authors reviewed the manuscript.
Acknowledgements
We thank Xiuhua Liu, the College of Chemistry and Chemical
Engineering of Henan University for DNA binding detection. We
also thank the Guangdong Provincial Key Laboratory of Malignant
Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial
Hospital, Sun Yat-Sen University for flow cytometry detection.
References
[1] D.S. Hsu, B.S. Balakumaran, C.R. Acharya, V. Vlahovic, K.S. Walters, K. Garman,
et al., Pharmacogenomic strategies provide a rational approach to the
treatment of cisplatin-resistant patients with advanced cancer, J. Clin. Oncol.
25 (2007) 4350–4357.
[2] C.A. Rabik, M.E. Dolan, Molecular mechanisms of resistance and toxicity
associated with platinating agents, Cancer Treat. Rev. 33 (2007) 9–23.
[3] E.R. Jamieson, S.J. Lippard, Structure, recognition, and processing of cisplatin-
DNA adducts, Chem. Rev. 99 (1999) 2467–2498.
[4] E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Cellular and
molecular pharmacology of oxaliplatin, Mol. Cancer Ther. 1 (2002) 227–235.
[5] P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, et al.,
A phase 2 study of bortezomib in relapsed, refractory myeloma, New Engl. J.
Med. 348 (2003) 2609–2617.
[6] J. Adams, The proteasome: structure, function, and role in the cell, Cancer
Treat. Rev. 29 (Suppl. 1) (2003) 3–9.
[7] D. Komander, M.J. Clague, S. Urbe, Breaking the chains: structure and function
of the deubiquitinases, Nat. Rev. Mol. Cell Biol. 10 (2009) 550–563.
[8] J.M. Fraile, V. Quesada, D. Rodriguez, J.M. Freije, C. Lopez-Otin, Deubiquitinases
in cancer: new functions and therapeutic options, Oncogene 31 (2012) 2373–
2388.
[9] S. Hussain, Y. Zhang, P.J. Galardy, DUBs and cancer: the role of deubiquitinating
enzymes as oncogenes, non-oncogenes and tumor suppressors, Cell Cycle 8
(2009) 1688–1697.
[10] A. Peth, N. Kukushkin, M. Bosse, A.L. Goldberg, Ubiquitinated proteins activate
the proteasomal ATPases by binding to Usp14 or Uch37 homologs, J. Biol.
Chem. 288 (2013) 7781–7790.
[11] D. Finley, Recognition and processing of ubiquitin-protein conjugates by the
proteasome, Annu. Rev. Biochem. 78 (2009) 477–513.
[12] P. D’Arcy, S. Linder, Molecular pathways: translational potential of
deubiquitinases as drug targets, Clin. Cancer Res. 20 (2014) 3908–3914.
[13] N.F. Bence, R.M. Sampat, R.R. Kopito, Impairment of the ubiquitin-proteasome
system by protein aggregation, Science 292 (2001) 1552–1555.
[14] H. Huang, X. Zhang, S. Li, N. Liu, W. Lian, E. McDowell, et al., Physiological
levels of ATP negatively regulate proteasome function, Cell Res. 20 (2010)
1372–1385.[15] H. Yang, P. Zhou, H. Huang, D. Chen, N. Ma, Q.C. Cui, et al., Shikonin exerts
antitumor activity via proteasome inhibition and cell death induction in vitro
and in vivo, Int. J. Cancer 124 (2009) 2450–2459.
[16] N. Liu, X. Li, H. Huang, C. Zhao, S. Liao, C. Yang, et al., Clinically used
antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and
inhibits tumor growth, Oncotarget 5 (2014) 5453–5471.
[17] H. Huang, N. Liu, H. Guo, S. Liao, X. Li, C. Yang, et al., L-carnitine is an
endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo
and in vitro, PLoS One 7 (2012) e49062.
[18] X. Shi, X. Chen, X. Li, X. Lan, C. Zhao, S. Liu, et al., Gambogic acid induces
apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing
proteasome inhibition and caspase-dependent Bcr-Abl downregulation, Clin.
Cancer Res. 20 (2014) 151–163.
[19] L. Lu, A. Qin, H. Huang, P. Zhou, C. Zhang, N. Liu, et al., Shikonin extracted from
medicinal Chinese herbs exerts anti-inflammatory effect via proteasome
inhibition, Eur. J. Pharmacol. 658 (2011) 242–247.
[20] W. Zhong, J.S. Yu, W. Huang, K. Ni, Y. Liang, Spectroscopic studies of interaction
of chlorobenzylidine with DNA, Biopolymers 62 (2001) 315–323.
[21] S. Kashanian, M.M. Khodaei, P. Pakravan, Spectroscopic studies on the
interaction of isatin with calf thymus DNA, DNA Cell Biol. 29 (2010) 639–646.
[22] C.Q. Jiang, J.X. He, J.S. Wang, [Studies on the interaction mode between
polymyxin B sulfate and DNA with EB as a fluorescence probe], Guang pu xue
yu guang pu fen xi = Guang pu 22 (2002) 103–106.
[23] C.E. Redon, J.S. Dickey, W.M. Bonner, O.A. Sedelnikova, Gamma-H2AX as a
biomarker of DNA damage induced by ionizing radiation in human peripheral
blood lymphocytes and artificial skin, Adv Space Res. 43 (2009) 1171–1178.
[24] N. Liu, C. Liu, X. Li, S. Liao, W. Song, C. Yang, et al., A novel proteasome inhibitor
suppresses tumor growth via targeting both 19S proteasome deubiquitinases
and 20S proteolytic peptidases, Sci. Rep. 4 (2014) 5240.
[25] M. Hu, P. Li, L. Song, P.D. Jeffrey, T.A. Chenova, K.D. Wilkinson, et al., Structure
and mechanisms of the proteasome-associated deubiquitinating enzyme
USP14, EMBO J. 24 (2005) 3747–3756.
[26] T.K. Maiti, M. Permaul, D.A. Boudreaux, C. Mahanic, S. Mauney, C. Das, Crystal
structure of the catalytic domain of UCHL5, a proteasome-associated human
deubiquitinating enzyme, reveals an unproductive form of the enzyme, FEBS J.
278 (2011) 4917–4926.
[27] K. Lee, J.E. Kang, S.K. Park, Y. Jin, K.S. Chung, H.M. Kim, et al., LW6, a novel HIF-1
inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of
VHL in a colon cancer cell line, Biochem. Pharmacol. 80 (2010) 982–989.
[28] E. Rico-Bautista, C.C. Yang, L. Lu, G.P. Roth, D.A. Wolf, Chemical genetics
approach to restoring p27Kip1 reveals novel compounds with antiproliferative
activity in prostate cancer cells, BMC Biol. 8 (2010) 153.
[29] D. Niewerth, G. Jansen, L.F. Riethoff, J. van Meerloo, A.J. Kale, B.S. Moore, et al.,
Antileukemic activity and mechanism of drug resistance to the marine
Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib),
Mol. Pharmacol. 86 (2014) 12–19.
[30] D. Chen, Q.C. Cui, H. Yang, Q.P. Dou, Disulfiram, a clinically used anti-
alcoholism drug and copper-binding agent, induces apoptotic cell death in
breast cancer cultures and xenografts via inhibition of the proteasome activity,
Cancer Res. 66 (2006) 10425–10433.
[31] D. Chen, Q.C. Cui, H. Yang, R.A. Barrea, F.H. Sarkar, S. Sheng, et al., Clioquinol, a
therapeutic agent for Alzheimer’s disease, has proteasome-inhibitory,
androgen receptor-suppressing, apoptosis-inducing, and antitumor activities
in human prostate cancer cells and xenografts, Cancer Res. 67 (2007) 1636–
1644.
[32] B. Cvek, V. Milacic, J. Taraba, Q.P. Dou, Ni(II), Cu(II), and Zn(II)
diethyldithiocarbamate complexes show various activities against the
proteasome in breast cancer cells, J. Med. Chem. 51 (2008) 6256–6258.
[33] D. Tomco, S. Schmitt, B. Ksebati, M.J. Heeg, Q.P. Dou, C.N. Verani, Effects of
tethered ligands and of metal oxidation state on the interactions of cobalt
complexes with the 26S proteasome, J. Inorg. Biochem. 105 (2011) 1759–
1766.
[34] M. Vieites, P. Smircich, B. Parajon-Costa, J. Rodriguez, V. Galaz, C. Olea-Azar,
et al., Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-
oxide metal complexes having an inhibitory effect on parasite-specific
fumarate reductase, J. Biol. Inorg. Chem. 13 (2008) 723–735.
[35] N. Pabla, S. Huang, Q.S. Mi, R. Daniel, Z. Dong, ATR-Chk2 signaling in p53
activation and DNA damage response during cisplatin-induced apoptosis, J.
Biol. Chem. 283 (2008) 6572–6583.
[36] V. Kapuria, L.F. Peterson, D. Fang, W.G. Bornmann, M. Talpaz, N.J. Donato,
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome
formation and tumor cell apoptosis, Cancer Res. 70 (2010) 9265–9276.
[37] P. D’Arcy, S. Brnjic, M.H. Olofsson, M. Fryknas, K. Lindsten, M. De Cesare, et al.,
Inhibition of proteasome deubiquitinating activity as a new cancer therapy,
Nat. Med. 17 (2011) 1636–1640.
[38] B. Zhou, Y. Zuo, B. Li, H. Wang, H. Liu, X. Wang, et al., Deubiquitinase inhibition
of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-
kappaB inhibition and p53 reactivation in human lung cancer cells, Mol.
Cancer Ther. 12 (2013) 1381–1392.
[39] K. Coughlin, R. Anchoori, Y. Iizuka, J. Meints, L. MacNeill, R.I. Vogel, et al.,
Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer
in vitro and in vivo via exacerbating unfolded protein responses, Clin. Cancer
Res. 20 (2014) 3174–3186.
[40] X. Wang, P. D’Arcy, T.R. Caulfield, A. Paulus, K. Chitta, C. Mohanty, et al.,
Synthesis and evaluation of derivatives of the proteasome deubiquitinase
inhibitor b-AP15, Chem. Biol. Drug. Des. (2015).
38 C. Zhao et al. / Biochemical Pharmacology 116 (2016) 22–38[41] B.H. Lee, M.J. Lee, S. Park, D.C. Oh, S. Elsasser, P.C. Chen, et al., Enhancement of
proteasome activity by a small-molecule inhibitor of USP14, Nature 467
(2010) 179–184.
[42] M. Bazzaro, M.K. Lee, A. Zoso, W.L. Stirling, A. Santillan, M. Shih Ie, et al.,
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome
inhibitor-induced apoptosis, Cancer Res. 66 (2006) 3754–3763.
[43] M. Bazzaro, Z. Lin, A. Santillan, M.K. Lee, M.C. Wang, K.C. Chan, et al., Ubiquitin
proteasome system stress underlies synergistic killing of ovarian cancer cellsby bortezomib and a novel HDAC6 inhibitor, Clin. Cancer Res. 14 (2008) 7340–
7347.
[44] L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, X. Li, et al., Selective killing of
cancer cells by a small molecule targeting the stress response to ROS, Nature
475 (2011) 231–234.
[45] X. Li, S. Liu, H. Huang, N. Liu, C. Zhao, S. Liao, et al., Gambogic acid is a tissue-
specific proteasome inhibitor in vitro and in vivo, Cell Rep. 3 (2013) 211–222.
